The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Subscribe To Our Newsletter & Stay Updated
